Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-3S in HIV-1 Infection (IPROTECT1)
NCT02041247Phase 2Unknown
- Sponsor
- InnaVirVax
- Start
- Jan 2014
- Primary completion
- Sep 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of VAC-3S in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by InnaVirVax. Primary endpoint: anti-3S antibodies titer at 24 weeks. Status: unknown.
02
Drugs
VAC-3S
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02041247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041247.